GH Optimization Stack
CJC-1295 (no DAC) + Ipamorelin
Optimize growth hormone levels for improved body composition, recovery, sleep quality, and anti-aging benefits
Overview
Considered the "gold standard" growth hormone secretagogue combination. CJC-1295 (also called Mod GRF 1-29) acts as a GHRH analog to stimulate GH release, while Ipamorelin is a selective ghrelin mimetic that amplifies the pulse without significantly raising cortisol or prolactin. Together they produce a synergistic GH pulse that mimics natural physiology.
Component Peptides
GHRH analog — stimulates pituitary to release growth hormone in a pulsatile fashion
Selective GH secretagogue — amplifies GH pulse with minimal cortisol/prolactin elevation
Expected Timeline
Improved sleep quality within 1-2 weeks. Body composition changes at 4-8 weeks. Skin and recovery improvements at 8-12 weeks. Full benefits typically realized by 12-16 weeks.
Safety Notes
- Must be taken on empty stomach (food blunts GH release)
- May cause water retention, particularly in the first few weeks
- Numbness/tingling in extremities may occur (carpal tunnel-like symptoms)
- Avoid using with exogenous GH — redundant and may cause excessive IGF-1
- Both peptides are WADA-prohibited
Bloodwork Recommendations
- IGF-1 levels (baseline and at 6-8 weeks)
- Fasting glucose and HbA1c (GH can affect insulin sensitivity)
- Comprehensive metabolic panel
- Thyroid panel (TSH, free T3, free T4)
Contraindications
- Active cancer or cancer history (GH promotes cell proliferation)
- Diabetic or pre-diabetic individuals (GH elevates blood glucose)
- Active acromegaly or pituitary disorders
- Competitive athletes subject to WADA drug testing
- Pregnancy or breastfeeding
Evidence Assessment
Both peptides have been studied individually in human trials. CJC-1295 (with DAC) showed sustained GH elevation in clinical studies. Ipamorelin has Phase II trial data showing dose-dependent GH release. The combination is widely used clinically at anti-aging and hormone optimization clinics, though the specific combination lacks dedicated RCTs.
References
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.